Sell 11/20/2024Downgrade
Yubo International Biotech Limited (YBGJ) was downgraded to E+ from D- on 11/20/2024 due to a significant decline in the total return index, solvency index and growth index. Debt to equity increased from -0.26 to -0.19, earnings per share declined from -$0.0044 to -$0.0048, and the quick ratio declined from 0.13 to 0.11.

Sell 6/5/2024Upgraded
Yubo International Biotech Limited (YBGJ) was upgraded to D- from E+ on 6/5/2024 due to a noticeable increase in the solvency index, growth index and total return index. Operating cash flow increased 78.44% from -$558.4 to -$120.4, earnings per share increased from -$0.0043 to -$0.0031, and EBIT increased 20.86% from -$517.3 to -$409.4.

Sell 4/19/2024Downgrade
Yubo International Biotech Limited (YBGJ) was downgraded to E+ from D- on 4/19/2024 due to a significant decline in the growth index and solvency index. Operating cash flow declined 11,268% from $5 to -$558.4, EBIT declined 8,182.81% from $6.4 to -$517.3, and earnings per share declined from $0.0001 to -$0.0043.

Sell 11/22/2023Upgraded
Yubo International Biotech Limited (YBGJ) was upgraded to D- from E+ on 11/22/2023 due to a substantial increase in the total return index, growth index and solvency index. Total revenue increased 30,507.14% from $1.4 to $428.5, operating cash flow increased 103.27% from -$152.9 to $5, and earnings per share increased from -$0.0031 to $0.0001.

Sell 3/14/2023Downgrade
Yubo International Biotech Limited (YBGJ) was downgraded to E+ from D- on 3/14/2023 due to a decline in the total return index.

Sell 2/23/2023Upgraded
Yubo International Biotech Limited (YBGJ) was upgraded to D- from E+ on 2/23/2023 due to an increase in the total return index.

Sell 2/8/2023Downgrade
Yubo International Biotech Limited (YBGJ) was downgraded to E+ from D- on 02/08/2023.

Sell 11/18/2022Upgraded
Yubo International Biotech Limited (YBGJ) was upgraded to D- from E+ on 11/18/2022 due to a large increase in the growth index, volatility index and total return index. Operating cash flow increased 413.64% from -$17.6 to $55.2, total revenue increased 82.5% from $8 to $14.6, and earnings per share increased from -$0.0042 to -$0.002.

Sell 5/25/2022Downgrade
Yubo International Biotech Limited (YBGJ) was downgraded to E+ from D- on 5/25/2022 due to a decline in the volatility index and total return index.

Sell 5/9/2022Upgraded
Yubo International Biotech Limited (YBGJ) was upgraded to D- from E+ on 5/9/2022 due to a noticeable increase in the valuation index and volatility index.

Sell 4/20/2022Downgrade
Yubo International Biotech Limited (YBGJ) was downgraded to E+ from D- on 4/20/2022 due to a significant decline in the solvency index, efficiency index and growth index. Operating cash flow declined 106.82% from -$30.8 to -$63.7, the quick ratio declined from 0.28 to 0.21, and net income declined 18% from -$336.6 to -$397.2.

Sell 10/1/2021Upgraded
Yubo International Biotech Limited (YBGJ) was upgraded to D- from E on 10/1/2021 due to a substantial increase in the growth index, solvency index and volatility index. Operating cash flow increased 107.6% from -$1M to $76.2, earnings per share increased from -$0.0037 to -$0.0031, and EBIT increased 15.62% from -$438.6 to -$370.1.

Sell 7/1/2021Upgraded
Yubo International Biotech Limited (YBGJ) was upgraded to E from E- on 07/01/2021.

Sell 5/26/2021None
Yubo International Biotech Limited (YBGJ) was downgraded to E- from U on 05/26/2021.